Publications 2025

Moore KLF, Rognvaldsson S, Szabo AG, Vaitekėnaitė V, Loigom D, Genell A, Thorsen J, Norgaard JN, Thorsteinsdottir S, Knut-Bojanowska D, Lysen A, Schjesvold F, Peceliunas V, Kaare A, Palk K, Parnat M, Sigurdsson A, Vangsted AJ, Blimark CH (2025)
Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group
Haematologica (in press)
DOI 10.3324/haematol.2025.287344, PubMed 40905090

Publications 2024

Nørgaard JN, Moore KLF, Slørdahl TS, Vik A, Tvedt THA, Schjesvold F (2024)
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study
Blood Cancer J, 14 (1), 60
DOI 10.1038/s41408-024-01047-1, PubMed 38594252

Røra M, Solberg MS, Moore KLF, Slørdahl TS (2024)
Incidence and prevention of skeletal-related events in multiple myeloma patients: A population-based real-world experience
EJHaem, 5 (4), 669-676
DOI 10.1002/jha2.928, PubMed 39157600

Publications 2023

Moore KLF, Turesson I, Genell A, Klausen TW, Knut-Bojanowska D, Redder L, Sverrisdottir I, Thorsen J, Vangsted AJ, Blimark CH (2023)
Improved survival in myeloma patients-a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden
Haematologica, 108 (6), 1640-1651
DOI 10.3324/haematol.2021.280424, PubMed 36300775

Publications 2013

Moore KL, Kildahl-Andersen O, Kildahl-Andersen R, Tjønnfjord GE (2013)
Uncommon adverse effect of a common medication
Tidsskr Nor Laegeforen, 133 (2), 165
DOI 10.4045/tidsskr.12.0494, PubMed 23344600